Literature DB >> 11574203

New perspectives on macrolide antibiotics.

J C Pechère1.   

Abstract

Macrolides are not used exclusively for the treatment of community-acquired respiratory tract infections. Their ability to penetrate cells makes them highly suitable for the treatment of diseases caused by intracellular pathogens, such as non-gonococcal urethritis and trachoma. Azithromycin is approved for these indications. Clinical studies have also been conducted, or are currently being carried out, to assess the use of macrolides in the treatment of atherosclerosis, eradication of Helicobacter pylori and the management of life-threatening gastrointestinal diseases, cystic fibrosis and malaria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574203     DOI: 10.1016/s0924-8579(01)00393-4

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Helicobacter pylori is invasive and it may be a facultative intracellular organism.

Authors:  Andre Dubois; Thomas Borén
Journal:  Cell Microbiol       Date:  2007-03-26       Impact factor: 3.715

2.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

Review 3.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

4.  Combination therapy for airflow limitation in COPD.

Authors:  Mostafa Ghanei; Leila Hoseini Nezhad; Ali Amini Harandi; Farshid Alaeddini; Majid Shohrati; Jafar Aslani
Journal:  Daru       Date:  2012-08-28       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.